[A24-28] Idecabtagene vicleucel (multiple myeloma, at least 3 prior therapies) – Benefit assessment according to §35a Social Code Book V
Last updated 03.06.2024
Project no.:
A24-28
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Withdrawn commission
Department/Division:
Drug Assessment
Topic:
Cancer
| Project no. | Title | Status |
|---|---|---|
| G22-01 | Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A24-35 | Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |